BioCryst Pharmaceuticals | Zinsaufwendungen Für Schuld



Interest Expense On Debt Veränderung Datum
Alnylam Pharmaceuticals USD 38.65M 325K 2025-03
Daiichi Sankyo 7.08B 4.54B 2025-03
DBV Technologies 784.71K 632.24K 2022-06
Gilead Sciences USD 260M 12M 2025-03
GlaxoSmithKline 162M 11M 2025-03
Glaxosmithkline 178.05M 24.73M 2024-12
Incyte USD 660K 241K 2025-03
Ionis Pharmaceuticals USD 19M 16.41M 2025-03
Neurocrine Biosciences USD 1.1M 0 2024-03
PTC Therapeutics USD 43.35M 1.24M 2024-12
Regeneron Pharmaceuticals USD 8.7M 1.8M 2025-03
Roche Holding CHF 311.5M 1000K 2024-12
Sarepta Therapeutics USD 4.92M 86K 2024-09
Ultragenyx Pharmaceutical 15.52M 190K 2024-12
Vertex Pharmaceuticals USD 2.8M 4.7M 2024-12



BioCryst Pharmaceuticals Zinsaufwendungen Für Schuld - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Jul 2025.